Actinium Pharmaceuticals (ATNM) News Today $1.26 -0.06 (-4.55%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.40%) As of 04/15/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMApril 15 at 10:00 PM | globenewswire.comKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmApril 15 at 8:57 PM | prnewswire.comActinium Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 27, 2025 Deadline to file Lead Plaintiff MotionApril 15 at 6:57 PM | globenewswire.comThe Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ATNMApril 15 at 1:03 PM | globenewswire.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitApril 14 at 6:37 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMApril 14 at 5:58 PM | prnewswire.comATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the ClassApril 14 at 5:29 PM | prnewswire.comATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 13 at 9:09 AM | globenewswire.comActinium Pharmaceuticals (NYSE:ATNM) Cut to "Sell" at StockNews.comApril 13 at 3:01 AM | americanbankingnews.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 11, 2025 | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNMApril 11, 2025 | prnewswire.comThe Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. ...April 10, 2025 | gurufocus.comThe Gross Law Firm Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATNMApril 10, 2025 | prnewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMApril 9, 2025 | globenewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 9, 2025 | prnewswire.comThe Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming DeadlineApril 9, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumApril 9, 2025 | globenewswire.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitApril 8, 2025 | prnewswire.comShareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)April 8, 2025 | businesswire.comShareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)April 8, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMApril 8, 2025 | prnewswire.comActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNMApril 8, 2025 | prnewswire.comATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc.April 7, 2025 | prnewswire.comShareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNMApril 7, 2025 | prnewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 4, 2025 | globenewswire.comActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & ...April 4, 2025 | gurufocus.comActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNMApril 4, 2025 | prnewswire.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitApril 3, 2025 | prnewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMApril 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMApril 3, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumApril 2, 2025 | markets.businessinsider.comActinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday.April 2, 2025 | marketbeat.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 1, 2025 | prnewswire.comKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmApril 1, 2025 | investing.comACTINIUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmMarch 31, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMarch 31, 2025 | prnewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 30, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMarch 30, 2025 | investing.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumMarch 30, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMarch 30, 2025 | globenewswire.comATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMarch 29, 2025 | prnewswire.comWhat is HC Wainwright's Forecast for ATNM FY2027 Earnings?Actinium Pharmaceuticals, Inc. (NYSE:ATNM - Free Report) - Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst J. PantginisMarch 29, 2025 | marketbeat.comActinium Pharmaceuticals unveils novel prostate cancer therapyMarch 29, 2025 | investing.comATNM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. InvestorsMarch 29, 2025 | markets.businessinsider.comActinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club TodayMarch 28, 2025 | morningstar.comInvestor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action LawsuitMarch 28, 2025 | prnewswire.comRosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsMarch 28, 2025 | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMMarch 28, 2025 | globenewswire.comSecurities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. CruzMarch 28, 2025 | businesswire.comGainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)March 28, 2025 | globenewswire.com Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNM Media Mentions By Week ATNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATNM News Sentiment▼0.010.79▲Average Medical News Sentiment ATNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATNM Articles This Week▼174▲ATNM Articles Average Week Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Canopy Growth News Neurogene News DBV Technologies News Innate Pharma News Fulcrum Therapeutics News Nanobiotix News Actuate Therapeutics News Molecular Partners News Rezolute News AC Immune News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ATNM) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNM Stock Free ATNM Stock Alerts